WHO Framework for Engagement with Non-State Actors

WHO Framework for Engagement with Non-State Actors
Name	WHO Framework for Engagement with Non-State Actors
Formation	2016
Type	Policy framework
Headquarters	Geneva
Parent organization	World Health Organization

WHO Framework for Engagement with Non-State Actors is a policy instrument developed by the World Health Organization to regulate interactions between WHO and a range of external actors including non-governmental organization, private sector, philanthropic foundation, academic institution, and professional association. The Framework sets standards for transparency, accountability, and risk management in engagements with entities such as the Bill & Melinda Gates Foundation, Médecins Sans Frontières, and multinational corporations like Pfizer, GlaxoSmithKline, and Johnson & Johnson. It was adopted amid debates involving stakeholders from World Health Assembly, Member States, and civil society groups including Amnesty International and Oxfam.

Overview

The Framework articulates WHO’s formal approach to partnerships and interactions, positioning WHO within a landscape that includes United Nations agencies like UNICEF, UNDP, and UNICEF’s partners, alongside actors from the World Bank and International Monetary Fund. It aims to balance cooperation with risk mitigation in contexts similar to those addressed by treaties such as the Framework Convention on Tobacco Control and instruments like the International Health Regulations (2005). The document outlines categories of non-state actors, sets out exclusion criteria, and prescribes procedures for due diligence and public disclosure to align engagements with WHO’s constitutional objectives as debated in the World Health Assembly.

Scope and Definitions

The Framework defines “non-state actors” to include non-governmental organizations, private sector entities, philanthropic foundations, and academic institutions, distinguishing them from Member States and intergovernmental organizations such as European Union bodies or African Union organs. It explicitly references interactions relevant to actors like Médecins Sans Frontières, GAVI Alliance, Global Fund to Fight AIDS, Tuberculosis and Malaria, and corporations involved in pharmaceutical industry activities, drawing parallels to governance models used by entities such as International Committee of the Red Cross and World Trade Organization consultative arrangements. Definitions also delimit excluded actors, referencing precedents from Framework Convention on Tobacco Control policies concerning tobacco industry interference.

Principles and Guiding Rules

The Framework enumerates core principles—transparency, accountability, risk assessment, and protecting normative functions—echoing standards from documents such as the United Nations Global Compact and OECD guidance on conflict of interest. It emphasizes safeguarding WHO’s normative, standard-setting, and regulatory roles against undue influence from entities like Philip Morris International or other contentious transnational corporations. The rules require adherence to WHO’s constitutional mandate as invoked in discussions at the World Health Assembly and align with ethical frameworks used by Harvard T.H. Chan School of Public Health, London School of Hygiene & Tropical Medicine, and Johns Hopkins Bloomberg School of Public Health.

Engagement Mechanisms and Procedures

The Framework prescribes concrete mechanisms: registration systems for non-state actors, due diligence similar to practices of the World Bank and European Medicines Agency, memoranda of understanding used by Bill & Melinda Gates Foundation partnerships, and criteria for technical collaboration with entities such as Centers for Disease Control and Prevention and Pasteur Institute. It details procedures for consultations, official relations with non-governmental organizations, and project-based agreements referencing procurement and compliance norms comparable to those of United Nations Office for Project Services and UNICEF supply chains. Operational steps include screening, risk assessment, public disclosure, and monitoring akin to governance processes at the Global Fund.

Governance, Accountability, and Conflict of Interest

Governance provisions require transparency comparable to reporting norms at Transparency International and stipulate conflict of interest management aligned with models from World Bank safeguards and OECD guidelines. The Framework mandates public registers, recurrent disclosure by participants—paralleling practices at European Commission advisory groups—and establishes oversight mechanisms echoing audit arrangements seen at International Criminal Court and World Health Assembly scrutiny. It sets boundaries on financial relationships, in-kind contributions, and technical assistance to reduce capture risks documented in analyses involving Kaiser Family Foundation and critiques of corporate influence in global health.

Implementation and Impact

Implementation has involved WHO secretariat units, regional offices such as WHO Regional Office for Europe and WHO Regional Office for Africa, and interaction with bodies like the Pan American Health Organization and WHO Regional Office for the Eastern Mediterranean. Early impacts include clarified processes for partnership approvals and enhanced disclosure of collaborations with entities including GAVI Alliance, Bill & Melinda Gates Foundation, and private firms like Novartis and Sanofi. Assessment studies by independent evaluators, think tanks such as the Center for Global Development and academic reviews in journals including The Lancet and BMJ have examined effects on policymaking, operational efficiency, and risk mitigation.

Criticisms and Controversies

Critics from Public Citizen, People’s Health Movement, and advocacy groups like Corporate Accountability argue the Framework insufficiently curbs corporate influence, citing contested engagements with pharmaceutical firms and controversial donors including Bill & Melinda Gates Foundation. Debates echo controversies from the Commission on Information and Accountability era and disputes over the Global Fund’s private sector partnerships. Other commentators from institutions like University of Oxford and University College London have highlighted implementation gaps, uneven application across regions, and challenges in enforcing conflict of interest provisions, provoking calls for reform at sessions of the World Health Assembly.

Category:World Health Organization policies